Study of SZ1003 injection for advanced liver cancer
Part of Cancer clinical trials.
This trial tests an experimental drug called SZ1003 for people with advanced liver cancer that has not responded to at least two prior treatments. The drug targets a protein called GPC3, which is often found on liver cancer cells. The goal is to see if it can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have advanced liver cancer that has worsened after at least two standard treatments.
- Your cancer must test positive for a protein called GPC3 (a lab test on a tumor sample).
- You must have at least one tumor that can be measured or evaluated on imaging scans.
- Your liver function must be relatively good (Child-Pugh class A or B, score 7 or less).
- You must be physically active enough to have an ECOG score of 0 or 1 (able to do light work or be fully active).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy, called CAR-T cells, that are engineered to target a protein called GPC3 found on liver cancer cells. It is for people with advanced liver cancer that has not responded to previous treatments.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This trial is testing a new medicine, AZD9793, for people with advanced or metastatic solid tumors that have a specific marker called GPC3. The goal is to see if AZD9793 can help shrink or control the cancer.
This trial tests a new cell therapy called SN301A for people with advanced liver cancer that has a specific protein (GPC3) on the tumor cells. The goal is to see if this treatment can help when other treatments have stopped working.
This trial is testing a combination of three drugs (HLX10, HLX04, and HLX53) to find the best dose and see if they help people with advanced liver cancer who have not had systemic treatment before. The goal is to shrink tumors and improve survival.
This trial tests a new treatment called MTS105 for people with advanced liver cancer (HCC) that has not responded to standard therapies. It targets a protein called GPC3 found on some liver cancer cells, aiming to stop the cancer from growing.
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.